A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers
- PMID: 18186066
- DOI: 10.1002/jbm.a.31784
A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers
Abstract
To develop an intravenous nanoparticle delivery system for a cancer drug (i.e., DHAQ, mitoxantrone), the synthesis of a biodegradable polyester polymer with hydrophilic polyethylene glycol chains, preparation of DHAQ-loaded nanoparticles from such polymer and biodistribution of the drug-loaded particles were investigated in this article. Biodegradable monomethoxy poly(ethylene glycol)-poly (lactide-co-glycolide)-monomethoxy poly(ethylene glycol) (MeO-PEG-PLGA-PEG-OMe, PELGE) copolymers were synthesized by ring-opening polymerization as the drug carriers. A double emulsion method with dextran-70 as an emulsifier was employed to prepare the nanoparticles. DHAQ-PELGE nanoparticles and free DHAQ were employed for the in vivo biodistribution studies after intravenous administration through the tail veins in mice. At various time intervals, the mice were sacrificed and several organs and tissues harvested, including hearts, livers, spleens, lungs, kidneys, and blood. The DHAQ concentrations in the collected tissues and plasmas were determined using high performance liquid chromatography. The DHAQ concentrations in mice plasmas in the experimental groups were significantly higher than those in the control group and 3.72% of total administrations dosages (TAD) of these particles with DHAQ remained in circulation even 96 h after intravenous injection. Compared with the free DHAQ, DHAQ-loaded PELGE nanoparticles had longer circulation properties. Further research should be done for intravenous injection of this material as drug carriers.
Similar articles
-
Synthesis and characterization of MeO-PEG-PLGA-PEG-OMe copolymers as drug carriers and their degradation behavior in vitro.J Mater Sci Mater Med. 2007 Oct;18(10):2067-73. doi: 10.1007/s10856-007-3090-x. Epub 2007 Jun 9. J Mater Sci Mater Med. 2007. PMID: 17558481
-
Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.Nanomedicine. 2007 Dec;3(4):246-57. doi: 10.1016/j.nano.2007.09.004. Nanomedicine. 2007. PMID: 18068091
-
Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.Int J Pharm. 2007 Feb 22;331(1):123-32. doi: 10.1016/j.ijpharm.2006.09.015. Epub 2006 Sep 17. Int J Pharm. 2007. PMID: 17097246
-
PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications.J Control Release. 2014 Jun 10;183:77-86. doi: 10.1016/j.jconrel.2014.03.026. Epub 2014 Mar 24. J Control Release. 2014. PMID: 24675377 Review.
-
Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system.Int J Pharm. 2009 Oct 20;381(1):1-18. doi: 10.1016/j.ijpharm.2009.07.033. Epub 2009 Aug 5. Int J Pharm. 2009. PMID: 19664700 Review.
Cited by
-
PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.Adv Healthc Mater. 2022 Apr;11(8):e2101536. doi: 10.1002/adhm.202101536. Epub 2022 Jan 27. Adv Healthc Mater. 2022. PMID: 35032406 Free PMC article. Review.
-
Drug-loaded nano-microcapsules delivery system mediated by ultrasound-targeted microbubble destruction: A promising therapy method.Biomed Rep. 2013 Jul;1(4):506-510. doi: 10.3892/br.2013.110. Epub 2013 May 21. Biomed Rep. 2013. PMID: 24648976 Free PMC article. Review.
-
The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges.Int J Mol Sci. 2022 Jan 20;23(3):1140. doi: 10.3390/ijms23031140. Int J Mol Sci. 2022. PMID: 35163063 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources